A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

A Phase I, Single Ascending Dose Study of GEM103 (Recombinant Human Complement Factor H) in Patients with Geographic Atrophy

Purpose: To establish the safety, tolerability, pharmacokinetics, and pharmacodynamics of an intravitreal injection of recombinant human complement factor H (CFH), GEM103, in individuals with genetically defined age-related macular degeneration (AMD) and geographic atrophy (GA). Design: Phase I sing...

Full description

Bibliographic Details
Main Authors: Arshad M. Khanani, MD, MA, Raj K. Maturi, MD, Nika Bagheri, MD, Benjamin Bakall, MD, PhD, David S. Boyer, MD, Stephen S. Couvillion, MD, Dilsher S. Dhoot, MD, Nancy M. Holekamp, MD, Karim N. Jamal, MD, Dennis M. Marcus, MD, Dante Pieramici, MD, Aamir A. Aziz, BS, Kiran C. Patki, MD, William Z. Bridges, Jr., MD, Samuel B. Barone, MD
Format: Article
Language:English
Published: Elsevier 2022-06-01
Series:Ophthalmology Science
Subjects:
Age-related macular degeneration
Complement factor H
Complement regulation
GEM103
Geographic atrophy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666914522000434

Internet

http://www.sciencedirect.com/science/article/pii/S2666914522000434

Similar Items